Basilea Pharmaceutica Ltd. Logo
 
Search
 

News

 
 
Language
Year
Keyword
 
Tuesday, June 13. 2017
 
Basel, Switzerland, June 13, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has been awarded USD 54.8 million for two additional options on its existing contract with the Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response under Contract No. HHSO100201600002C, to support the phase 3 development of ceftobiprole. The total potential funding of up to approximately USD 108 million under the contract will enable Basilea to conduct two clinical phase 3 studies to evaluate Basilea's antibiotic ceftobiprole for the treatment of Staphylococcus aureus bacteremia (bloodstream infections) and acute bacterial skin and skin structure infections. The cross-supportive studies are part of the clinical phase 3 program aiming at regulatory approval of ceftobiprole in the United States.
 
more...
 
Monday, June 12. 2017
 
  • The Adult Brain Tumor Consortium (ABTC) is designed to develop more effective treatments for malignant brain tumors. It is funded by the US National Cancer Institute (NCI).
  • The ABTC will conduct a clinical phase 1 study to determine the safety and tolerability of Basilea's novel tumor checkpoint controller BAL101553 in newly diagnosed glioblastoma patients.
 
more...
 
Tuesday, June 06. 2017
 
Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel tumor checkpoint controller, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 2-6, 2017.
 
more...
 
Friday, June 02. 2017
 
Basel, Switzerland, June 2, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of August 1, 2017, Damian Heller will assume the role of General Counsel & Corporate Secretary and join the Extended Management Committee which reports to the CEO. Mr. Heller succeeds Elizabeth Rozek who will be leaving Basilea to relocate to the United States.
 
more...
 
Thursday, April 27. 2017
 
Basel, Switzerland, April 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2016, shareholders approved all agenda items proposed by the Board of Directors.
 
more...
 
Friday, April 21. 2017
 
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
 
more...
 
Thursday, April 06. 2017
 
  • BAL101553 targets tumor cell proliferation, adaptation to low oxygen and vascularization
  • Switch from weekly to daily oral dosing leads to reduced tumor anti-vascular activity while maintaining tumor growth inhibition
  • Combination with the anti-VEGF therapy bevacizumab shows enhanced anti-tumor response
 
more...
 
Monday, February 27. 2017
 
Basel, Switzerland, February 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its Board of Directors proposes Dr. Nicole Onetto for election as a non-executive member of the Board at its Annual General Meeting of Shareholders to be held on April 27, 2017.
 
more...
 
Monday, February 20. 2017
 
  • Cresemba® launched by Basilea in first European countries and marketed together with Zevtera®/Mabelio®
  • Entered into distribution and license agreements covering more than 40 countries for both Cresemba and Zevtera/Mabelio
  • Product sales of CHF 7.1 million in Europe and CHF 7.3 million royalties received on 2016 Cresemba US sales
  • CHF 289 million cash and financial investments at year-end
  • Initiation of ceftobiprole clinical phase 3 development program under BARDA agreement anticipated mid-2017 to support potential future US regulatory filing
 
more...
 
Thursday, December 29. 2016
 
Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee which reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who retires as of December 31, 2016. Ms. Eberhardt has served in various positions in Basilea's Corporate Department and Human Resources team since joining Basilea in 2006 and most recently was deputy Head of Global Human Resources.
 
more...
 
more back
Info